Anavex Life Sciences announced it was granted new U.S. Patent No. 11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office, or USPTO, for its patent application number 17/890,083. Anavex’s newest patent expands coverage of ANAVEX 2-73, or blarcamesine, therapy to ameliorate various conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein, or MeCP2, the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVXL:
- Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
- Biotech Alert: Searches spiking for these stocks today
- Anavex price target lowered to $40 from $54 at H.C. Wainwright
- Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Anavex provides update on Rett Syndrome Program
